1. Home
  2. CLLS vs ALT Comparison

CLLS vs ALT Comparison

Compare CLLS & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • ALT
  • Stock Information
  • Founded
  • CLLS 1999
  • ALT 1997
  • Country
  • CLLS France
  • ALT United States
  • Employees
  • CLLS N/A
  • ALT N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • CLLS Health Care
  • ALT Health Care
  • Exchange
  • CLLS Nasdaq
  • ALT Nasdaq
  • Market Cap
  • CLLS 299.0M
  • ALT 327.4M
  • IPO Year
  • CLLS 2007
  • ALT N/A
  • Fundamental
  • Price
  • CLLS $3.15
  • ALT $3.59
  • Analyst Decision
  • CLLS Buy
  • ALT Strong Buy
  • Analyst Count
  • CLLS 1
  • ALT 6
  • Target Price
  • CLLS $4.00
  • ALT $17.40
  • AVG Volume (30 Days)
  • CLLS 76.4K
  • ALT 2.4M
  • Earning Date
  • CLLS 11-03-2025
  • ALT 11-11-2025
  • Dividend Yield
  • CLLS N/A
  • ALT N/A
  • EPS Growth
  • CLLS N/A
  • ALT N/A
  • EPS
  • CLLS N/A
  • ALT N/A
  • Revenue
  • CLLS $63,438,000.00
  • ALT $20,000.00
  • Revenue This Year
  • CLLS N/A
  • ALT N/A
  • Revenue Next Year
  • CLLS $66.76
  • ALT $761,880.20
  • P/E Ratio
  • CLLS N/A
  • ALT N/A
  • Revenue Growth
  • CLLS 223.09
  • ALT N/A
  • 52 Week Low
  • CLLS $1.10
  • ALT $2.90
  • 52 Week High
  • CLLS $3.35
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 54.47
  • ALT 45.32
  • Support Level
  • CLLS N/A
  • ALT $3.54
  • Resistance Level
  • CLLS $3.35
  • ALT $3.72
  • Average True Range (ATR)
  • CLLS 0.15
  • ALT 0.16
  • MACD
  • CLLS -0.09
  • ALT 0.02
  • Stochastic Oscillator
  • CLLS 94.03
  • ALT 21.87

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: